ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans

Vaccine

Volumn 33, Issue 32, 2015, Pages 3953-3962

  Chung, Ka Yan ^a   Coyle, Elizabeth M ^a   Jani, Dewal ^b   King, Lisa R ^a   Bhardwaj, Rukmini ^a   Fries, Louis ^b   Smith, Gale ^b   Glenn, Gregory ^b   Golding, Hana ^a   Khurana, Surender ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NOVAVAX INC   (United States)

Author keywords

Adjuvant; Antibody affinity; Epitope; H7N7; H7N9; Hemagglutinin; Influenza; ISCOMATRIX (ISCO); Neutralization; Pandemic; Phage display; Vaccine; Virus

Indexed keywords

ADJUVANT; ANTIBODY; EPITOPE; HEMAGGLUTININ; HEMAGGLUTININ 1; HEMAGGLUTININ 2; INFLUENZA VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; CHOLESTEROL; DRUG COMBINATION; IMMUNOLOGICAL ADJUVANT; ISCOMATRIX; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY; PHOSPHOLIPID; SAPONIN; VIRUS ANTIBODY;

ANTIBODY AFFINITY; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; GENOME FRAGMENT PHAGE DISPLAY LIBRARY; GENOMIC FRAGMENT; HUMAN; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A (H7N9); INFLUENZA VACCINATION; INFLUENZA VIRUS A H7N9; KINETICS; PHAGE DISPLAY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BINDING DOMAIN; SERUM; SURFACE PLASMON RESONANCE; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS STRAIN; BLOOD; DRUG COMBINATION; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H7N9); PEPTIDE LIBRARY;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CHOLESTEROL; DRUG COMBINATIONS; EPITOPES; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; PEPTIDE LIBRARY; PHOSPHOLIPIDS; SAPONINS; SURFACE PLASMON RESONANCE; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84937527091     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.047     Document Type: Article

References (38)

1. Zhang Q., Shi J., Deng G., Guo J., Zeng X., He X., et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 2013, 341:410-414.
2. Zhu H., Wang D., Kelvin D.J., Li L., Zheng Z., Yoon S.W., et al. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science 2013, 341:183-186.
3. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013, 368:1888-1897.
4. Shi Y., Zhang W., Wang F., Qi J., Wu Y., Song H., et al. Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science 2013, 342:243-247.
5. Xiong X., Martin S.R., Haire L.F., Wharton S.A., Daniels R.S., Bennett M.S., et al. Receptor binding by an H7N9 influenza virus from humans. Nature 2013, 499:496-499.
6. Watanabe T., Kiso M., Fukuyama S., Nakajima N., Imai M., Yamada S., et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013, 501:551-555.
7. Liu Q., Zhou B., Ma W., Bawa B., Ma J., Wang W., et al. Analysis of recombinant H7N9 wild-type and mutant viruses in pigs shows that the Q226L mutation in HA is important for transmission. J Virol 2014, 88:8153-8165.
8. Dormitzer P.R., Suphaphiphat P., Gibson D.G., Wentworth D.E., Stockwell T.B., Algire M.A., et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013, 5:185ra68.
9. Smith G.E., Flyer D.C., Raghunandan R., Liu Y., Wei Z., Wu Y., et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013, 31:4305-4313.
10. Bart S.A., Hohenboken M., Della Cioppa G., Narasimhan V., Dormitzer P.R., Kanesa-Thasan N. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014, 6:234ra55.
11. Mulligan M.J., Bernstein D.I., Winokur P., Rupp R., Anderson E., Rouphael N., et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 2014, 312:1409-1419.
12. Couch R.B., Patel S.M., Wade-Bowers C.L., Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS ONE 2012, 7:e49704.
13. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
14. Maraskovsky E., Schnurr M., Wilson N.S., Robson N.C., Boyle J., Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol 2009, 87:371-376.
15. Schnurr M., Orban M., Robson N.C., Shin A., Braley H., Airey D., et al. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol 2009, 182:1253-1259.
16. Wilson N.S., Yang B., Morelli A.B., Koernig S., Yang A., Loeser S., et al. ISCOMATRIX vaccines mediate CD8+T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol 2012, 90:540-552.
17. Wilson N.S., Duewell P., Yang B., Li Y., Marsters S., Koernig S., et al. Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. J Immunol 2014, 192:3259-3268.
18. Morelli A.B., Becher D., Koernig S., Silva A., Drane D., Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 2012, 61:935-943.
19. Liu Y.V., Massare M.J., Pearce M.B., Sun X., Belser J.A., Maines T.R., et al. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. Vaccine 2015, 33:2152-2158.
20. Fries L.F., Smith G.E., Glenn G.M. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013, 369:2564-2566.
21. Khurana S., Suguitan A.L., Rivera Y., Simmons C.P., Lanzavecchia A., Sallusto F., et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med 2009, 6:e1000049.
22. Khurana S., Chearwae W., Castellino F., Manischewitz J., King L.R., Honorkiewicz A., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010, 2:15ra5-25ra.
23. Khurana S., Verma N., Yewdell J.W., Hilbert A.K., Castellino F., Lattanzi M., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011, 3:85ra48.
24. Khurana S., Wu J., Verma N., Verma S., Raghunandan R., Manischewitz J., et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011, 85:10945-10954.
25. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
26. Khurana S., Coyle E.M., Verma S., King L.R., Manischewitz J., Crevar C.J., et al. H5 N-terminal beta sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine. Vaccine 2014, 32:6421-6432.
27. Khurana S., Verma N., Talaat K.R., Karron R.A., Golding H. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis 2011, 205:610-620.
28. Khurana S., Wu J., Dimitrova M., King L.R., Manischewitz J., Graham B.S., et al. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis 2013, 208:413-417.
29. Osterholm M.T., Ballering K.S., Kelley N.S. Major challenges in providing an effective and timely pandemic vaccine for influenza A(H7N9). JAMA 2013, 309:2557-2558.
30. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23:5751-5759.
31. Pushko P., Tumpey T.M., Van Hoeven N., Belser J.A., Robinson R., Nathan M., et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007, 25:4283-4290.
32. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008, 3:e1501.
33. Halliley J.L., Khurana S., Krammer F., Fitzgerald T., Coyle E.M., Chung K.Y., et al. High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine. J Infect Dis 2015, pii: jiv210. [Epub ahead of print].
34. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357:1937-1943.
35. Belshe R.B., Frey S.E., Graham I.L., Anderson E.L., Jackson L.A., Spearman P., et al. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. JAMA 2014, 312:1420-1428.
36. Davis I.D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004, 101:10697-10702.
37. Pearse M.J., Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv Drug Delivery Rev 2005, 57:465-474.
38. Lin Y., Kwon T., Polo J., Zhu Y.F., Coates S., Crawford K., et al. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 2008, 82:7492-7503.